OncLive® On Air

Highlights from the PER® CME activity "Shifting the Paradigm in Small Cell Lung Cancer: Targeting Tumor Biology to Transform Patient Outcomes" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Charles M. Rudin, MD, PhD; Alex A. Adjei, MD, PhD; and Millie Das, MD; discuss the latest treatment advances for extensive-stage small cell lung cancer (ES-SCLC), including how to sequence bispecific T-cell engagers and antibody-drug conjugates and ways to manage adverse events associated with these newer therapies.

Earn CME credit by completing the full accredited activity (available through April 9, 2027):
https://www.gotoper.com/stp26sclc-activity

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc; Merck Sharp & Dohme, LLC; and Jazz Pharmaceuticals, Inc.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

In today’s episode Mazyar Shadman, MD, MPH, discussed results from a post hoc indirect comparison that evaluated zanubrutinib (Brukinsa) from phase 3 SEQUOIA trial (NCT03336333) compared with acalabrutinib (Calquence) plus venetoclax (Venclexta) from the phase 3 AMPLIFY trial (NCT03836261) in patients with treatment-naive chronic lymphocytic leukemia (CLL). Dr Shadman is a professor in the Clinical Research Division, medical director of Cellular Immunotherapy, and the Innovators Network Endowed Chair at Fred Hutchinson Cancer Center in Seattle, Washington.

In our exclusive interview, Dr Shadman began with a top-line overview of how the indirect comparison was conducted and the rationale behind it. After discussing the design of the comparison, Dr Shadman then dove into a conversation on the results of the study, in addition to how it will help oncologists and patients alike in the clinic. Finally, Dr Shadman looked to the future of CLL management and underscored what research he would like to see conducted following the comparison and its results.

Highlights from the PER® CME activity "Coffee Talk: Charting New Pathways With HER2 and TROP2 Therapies – From Early to Advanced Breast Cancer" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Hope S. Rugo, MD, FASCO; Giuseppe Curigliano, MD, PhD; Paolo Tarantino, MD, PhD; and Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS; discuss and debate recently published results of pivotal clinical trials in early-stage, HER2-positive breast cancer and their implications for patient care.

Earn CME credit by completing the full accredited activity (available through April 7, 2027):
https://www.gotoper.com/mbcc26coffeetalk-activity

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Highlights from the PER® CME activity "Facilitating Precision Pathways: Surgical Considerations in Breast Cancer for Tackling Barriers to Genetic Testing and Targeted Therapies" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Patrick I. Borgen, MD; Don S. Dizon, MD, FACP, FASCO; Kevin S. Hughes, MD, FACS; and Banu Arun, MD, FASCO; discuss how genetic testing drives breast cancer management from screening and surgical decisions to targeted systemic therapies.

Earn CME credit by completing the full accredited activity (available through April 3, 2027):
https://www.gotoper.com/mbcc26gbrca-activity

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AstraZeneca Pharmaceuticals and Merck Sharp & Dohme LLC.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Breast Cancer Briefing, hosted by Sara Nunnery, MD, MSCI, a breast medical oncologist and the director of Breast Cancer Research at Tennessee Oncology in Nashville, is a podcast series that breaks down the latest news in breast cancer research, one conversation at a time.

In today's episode, filmed live onsite at the 43rd Annual Miami Breast Cancer Conference, Dr Nunnery sat down with Neil M. Iyengar, MD, an associate professor and co-director of Breast Medical Oncology in the Department of Hematology and Medical Oncology at the Emory University School of Medicine, as well as the director of Survivorship Services at the Winship Cancer Institute of Emory University in Atlanta, Georgia.

Their conversation centered around lifestyle and medical interventions pertinent to breast cancer survivorship. Dr Iyengar explained that although endocrine therapies can be life-saving, they disrupt estrogen signaling, which can lead to cardiometabolic dysfunction, including increased risks for diabetes, heart disease, and bone health issues. He noted that weight gain associated with these treatments is often tied to the induction of a post-menopausal state, which disrupts energy homeostasis and promotes inflammation.

A key theme of the conversation was Dr Iyengar’s explanation of a "drug development paradigm" for lifestyle changes. Rather than offering generic advice, his research focuses on precision lifestyle interventions, treating diet and exercise as prescribed medical therapies with specific "doses". He highlighted that body mass index (BMI) is an insufficient tool for risk stratification, as high body fat despite a normal BMI is a significant risk factor for cancer recurrence.

The discussion also covered the rising use of GLP-1 receptor agonists to manage metabolic health. These drugs replicate natural hormones to maintain glycemic balance and reduce hunger. Dr Iyengar addressed the black box warning for thyroid cancer associated with this class of drugs, noting that although the data are mixed, the protective benefits against obesity-related cancers appear to outweigh the risks. Finally, he emphasized that exercise is a critical tool for managing treatment adverse effects like fatigue, noting that although starting is difficult, the "return on investment" for patient health is immense.

Welcome to OncLive On Air®! I’m your host today, Kyle Doherty.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we spoke with David Morris, MD, FACS, and Alan H. Bryce, MD. Dr Morris is the president of Urology Associates, PC, in Nashville, Tennessee. Dr Bryce is a medical oncologist and the chief clinical officer of City of Hope Cancer Center Phoenix in Arizona.

In our exclusive interview, Drs Morris and Bryce discussed the clinical implications of the FDA’s full approval of rucaparib (Rubraca) for BRCA mutation–associated metastatic castration-resistant prostate cancer (mCRPC), including the notable data that supported the regulatory decision and how this agent fits into the mCRPC treatment paradigm.

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School, both in Boston, Massachusetts.

In this episode, Dr Matulonis sat down with guest Katharine M. Esselen, MD, MBA. Dr Esselen is an attending gynecologic oncologist at Beth Israel Deaconess Medical Center and an assistant professor of obstetrics, gynecology, and reproductive biology at Harvard Medical School in Boston. 

Drs Matulonis and Esselen explored the growing effect of financial toxicity in gynecologic oncology, emphasizing how economic burden can influence access to care, treatment adherence, and patient outcomes. Dr Esselen, whose research focuses on patient-centered outcomes and value-based care, highlighted that financial toxicity extends beyond direct medical costs to include indirect burdens such as lost wages, childcare needs, transportation, and basic living expenses. 

To address these challenges, Dr Esselen and her colleagues developed a financial navigation program at Beth Israel Deaconess Medical Center. This initiative includes systematic screening for financial concerns and dedicated support from a financial navigator who connects patients with resources such as insurance optimization, transportation assistance, and financial aid programs. Implementation of this program significantly increased identification of at-risk patients and improved access to supportive services.

Importantly, Drs Matulonis and Esselen emphasized that financial toxicity is not only a quality-of-life issue but also a clinical one. Studies show that patients experiencing high financial burden are more likely to delay or forgo care and less likely to adhere to prescribed treatments, which may ultimately affect survival outcomes. Drs Matulonis and Esselen concluded the discussion by outlining the steps that can be taken to reduce financial burden on patients, underscoring the need for proactive screening, multidisciplinary support, and systemic change.

In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Katy Beckermann, MD, to discuss kidney cancer highlights from the 2026 Genitourinary Cancers Symposium. Dr Beckermann is director of Genitourinary Cancer Research at Tennessee Oncology in Franklin.

Their conversation focused on the clinical evolution of HIF-2 targeting, specifically the integration of belzutifan (Welireg) into earlier lines of therapy and novel combinations. Drs. Park and Beckerman examined the phase 3 LITESPARK-022 trial (NCT05239728), which evaluated adjuvant pembrolizumab (Keytruda) plus belzutifan in patients with clear cell renal cell carcinoma (ccRCC). Although the disease-free survival curves showed early and sustained separation, the experts noted that overall survival data remain immature and expressed concern regarding the rate of grade 3 adverse effects with the investigational combination, which may lead to overtreatment in the absence of enrichment biomarkers. However, they noted that a particularly strong efficacy signal was highlighted in the sarcomatoid patient population.

In the refractory setting, the phase 3 LITESPARK-011 trial (NCT04586231) comparing lenvatinib (Lenvima) plus belzutifan vs cabozantinib (Cabometyx) in patients with RCC was identified as practice-changing. This investigational combination was shown to increase the median progression-free survival (PFS) and generate durable responses.

The discussion also touched on frontline triplet regimens from the phase 1/2 KEYMAKER-U03 umbrella platform. Early data with pembrolizumab plus lenvatinib and belzutifan showed a median PFS that may influence future first-line clinical practice for patients with ccRCC.

The experts also emphasized proactive management of unique HIF-2 inhibitor–associated toxicities. They explained that anemia, driven by erythropoietin inhibition, is nearly universal and should be managed with aggressive erythropoietin or darbepoetin supplementation once hemoglobin levels drop below 10 g/dL. Furthermore, they recommended home pulse oximetry to monitor for hypoxia and baseline echocardiograms for TKI combinations to screen for reduced ejection fraction and volume overload.

Drs Park and Beckermann concluded by spotlighting the need for familiarity with these new agents to optimize patient outcomes.

Highlights from the PER® CME activity "Show Me the Data®: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Carrie L. Kitko, MD; Miguel-Angel Perales, MD; and Amandeep Salhotra, MD, discuss GVHD prophylaxis strategies and therapies to address treatment-naive and steroid-refractory chronic GVHD.

Earn CME credit by completing the full accredited activity (available through March 31, 2027):
https://www.gotoper.com/oncobyte-cgvhd

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from Incyte Corporation and Orca Bio.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

In today’s episode, we spoke with Ticiana Leal, MD, about variability in community practice and evolving treatment strategies for patients with small cell lung cancer (SCLC). Dr Leal is a professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, as well as the medical director of the Clinical Trials Office at Winship Cancer Institute in Atlanta, Georgia.

In our exclusive interview, Dr Leal began by discussing how SCLC management can differ widely across community settings according to how patients present. Leal emphasized the importance of quickly confirming a patient’s diagnosis and initiating treatment to avoid missing the critical window where chemotherapy could provide meaningful clinical benefit. However, Leal noted that the field still lacks predictive biomarkers to guide treatment selection. Accordingly, current strategies, including chemoimmunotherapy, maintenance approaches, and second-line options like tarlatamab-dlle (Imdelltra) and lurbinectedin (Zepzelca) are largely chosen based on clinical factors such as disease burden, comorbidities, and patient preferences.

The conversation then shifted to the challenge of treating patients who may not meet traditional clinical trial eligibility criteria due to poor performance status, comorbidities, or social vulnerabilities. Leal stated that a multidisciplinary approach, including collaboration with supportive care teams, is essential to optimize outcomes for these patients. She noted that potential solutions to restrictive trial eligibility criteria may include decentralizing trials, improving collaboration between academic and community centers, and providing additional patient support such as transportation and care navigation services.

Looking ahead, Leal emphasized the need for community practices to prepare for emerging therapies, including antibody-drug conjugates and novel immunotherapy approaches. Successfully integrating these treatments into everyday practice will require education, infrastructure development, and multidisciplinary collaboration, Leal imparted.